Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 5, 2004 - Issue 11
Submit an article Journal homepage
85
Views
12
CrossRef citations to date
0
Altmetric
Review

New phosphodiesterase inhibitors in the treatment of erectile dysfunction

Paul CB Anderson Good Hope Hospital, Sutton Coldfield, West Midlands, UK
,
Lyndon Gommersall University Hospital Birmingham, Edgbaston, Birmingham B17 2TH, UK
,
Dickon Hayne City Hospital, Dudley Road, Birmingham, UK
,
Manit Arya Royal Free Hampstead NHS Trust, Department of Urology, Pond Street, London NW3 2QG, UK
&
Hitendra RH Patel Royal Free Hampstead NHS Trust, Department of Urology, Pond Street, London NW3 2QG, UK. [email protected]
Pages 2241-2249 | Published online: 25 Feb 2005

Bibliography

  • MCKINLAY JB: The worldwide prevalence and epidemiology of erectile dysfunction. Int. J. Impot. Res. (2000) 12:S6.
  • CHUN J, CARSON CC: Physician-patient dialogue and clinical evaluation of erectile dysfunction. Urol. Clin. North. Am. (2001) 28:249–258.
  • GOLDSTEIN I, LUE TF, PADMA-NATHAN H, ROSEN RC, STEERS WD, WICKER PA: Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Eng]. J. Med. (1998) 338:1397.
  • MOBLEY DF, BAUM N: When patientsrequest the impotence pill. Postgrad. Med. (1998) 104:55.
  • FINK HA, MAC DONALD R, RUTKS IR, NELSON DB, WILT TJ: Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch. Int. Med. (2002) 162(12):1349–1360.
  • •A well presented review and analysis of all aspects of sildenafil, incorporating every relevant randomised trial published up to 2002.
  • LINCOLN TM: Cyclic GMP and mechanisms of vasodilation. Pharmacol Ther. (1989) 41:479.
  • CARVAJAL JA, GERMAIN AM, HUIDOBRO-TORO JP, WEINER CP: Molecular mechanism of cGMP-mediated smooth muscle relaxation. ". Cell. Physic] (2000) 184:409.
  • IGNARRO LJ, BUSH PA, BUGA GM et al.: Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem. Biophys. Res. Commun. (1990) 170:843–850.
  • CORBIN JC, FRANCIS S, WEBB D: Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology (2002) 60 (Suppl. 2B):4–11.
  • BLOUNT MA, BEASLEY A, ZORAGHI R et al.: Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Ma Pharm. (2004) 66(1):144–152.
  • CORBIN JD, BEASLEY A, BLOUNT MA, FRANCIS SH: Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). Neurochem. Int. (2004) 45(6)859–863.
  • PORST H: Phosphodiesterase type-5 inhibitors: a critical comparative analysis. EAU Update Series (2004) 2:56–63.
  • ••A succinct comparison of PDE-5inhibitors, written by a respected authority on the subject with conclusions that draw on his wealth of clinical experience.
  • PADMA-NATHAN H, EARDLEY I, KLONER RA, LATIES AM, MONTORSI F: A 4-year update on the safety of sildenafil citrate (Viagra). Urology (2002) 60(2 Suppl. 2):67–90.
  • BROCK, GB, McMAHON C, CHEN K et al.: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. Um]. (2002) 168:1332–1336.
  • •A recent and comprehensive analysis of five randomised, controlled trials, clearly demonstrating tadalafil's efficacy.
  • PADMA-NATHAN H, STECHER VJ, SWEENEY M, ORAZEM J, TSENG LJ, DERIESTHAL H: Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology (2003) 62(3):400–403.
  • HELLSTROM WJ: Vardenafil: a new approach to the treatment of erectile dysfunction. Curr. Um]. Rep. (2003) 4(6):479–487.
  • PORST H, PADMA-NATHAN H, GIULIANO F, ANGLIN G, VARANESE L, ROSEN R: Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 h after dosing: a randomized controlled trial. Urology (2003) 62(1):121–125.
  • RAJAGOPALAN P, MAZZU A, XIA C, DAWKINS R, SUNDARESAN P: Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. Clin. Pharmacol (2003) 43(3):260–267.
  • PATTERSON B, BEDDING A, JEWELL H et al.: Dose-normalised pharmacokinetics of tadalafil (IC351) administered as a single dose to health volunteers. hat. Impot. Res. (2001) 13\(Suppl. 4):543.
  • CORBIN JD, FRANCIS SH: Pharmacology of phosphodiesterase-5 inhibitors. Int. J. Clin. Practice (2002) 56(6):453–459.
  • BISCOFF E, MONDRITZKI T, NIEWOEHNER U, HANING H, ZIMMER D: Vardenafil improved erections in rabbits longer than expected from plasma half-life Int. .1. Impot. Res. (2002) 14\(Suppl. 4):P–009.
  • Pfizer Inc.: Viagra® (sildenafil) package insert. Pfizer Inc., New York, NY, USA (2003).
  • Bayer Pharmaceutical Corp.: Levitra® (vardenafil) package insert. Bayer Pharmaceutical Corp., West Haven, Conn., USA (2003).
  • Lilly ICOS LLC: Cialis® (tadalafil) package insert. Lilly ICOS LLC, Indianapolis, Ind. and Bothell, Wash, USA (2003).
  • PADMA-NATHAN H, STEERS WD, WICKER PA: Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Int. J. Clin. Practice (1998) 52(6)375–379.
  • HATZICHRISTOU D, MONTORSI F, BUVAT J, LAFERRIERE N, BANDEL TJ, PORST H: The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men. Eur. Um]. (2004) 45(5):634–641.
  • VON KEITZ A, RAJFER J, SE GAL S et al.: A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur. Um]. (2004) 45(4):499–507.
  • KUTHE A, MAGERT H, UCKERT S, FORSSMANN WG, STIEF CG, JONAS U: Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis. Eur. Um]. (2000) 38(1):108–114.
  • MCMURRAY JG, FELDMAN RA, AUERBACH SM, DE RIESTHAL H, WILSON N: Long-term effectiveness and tolerability of viagra in men with erectile dysfunction. Int. .1. Impot. Res. (2002) 14\(Suppl. 3):CP 5.53.
  • KLONER RA, MITCHELL M, EMMICK JT, Cardiovascular effects of tadalafil. Am. Cardiol (2003) 92(9A):37M–46M.
  • PORST H, KLONER RA, MOHAN P et al.: Cardiovascular safety of the selective PDE5 inhibitor vardenafil in patients with erectile dysfunction. Int. .1. Impot. Res. (2002) 14(Suppl.)4:P092.
  • ARRUDA-OLSON AM, MAHONEY DW, NEHRA A, LECKEL M, PELLIKKA PA: Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JA/VIA (2002) 287(6):719–725.
  • THADANI U, SMITH W, NASH S et al.: The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J. Am. Coll. Cardiol (2002) 40(11):2006–2012.
  • VICKERS MA, SATYANARAYANA R: Phosphodiesterase Type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int. I Impot. Res (2002) 14:466–471.
  • RENDELL MS, RAJFER J, WICKER PA, SMITH MD: Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA (1999) 281(5):421–426.
  • GOLDSTEIN I, YOUNG JM, FISCHER J et al.: Vardenafil, a new phosphodiesterase Type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes. Diabetes Care (2003) 26:777–783.
  • SAENZ DE TAJADA I, ANGLIN G, KNIGHT JR, EMMICK JT: Effects of tadalafil on erectile dysfunction on men with diabetes. Diabetes Care (2002) 25:2159–2164.
  • PADMA-NATHAN E, MCCULLOUGH AR, GIULIANO F, TOLER SM, WOHLHUTER C, SHPILSKY AB: Postoperative nightly administration of sildenafil citrate significantly improves the return of normal spontaneous erectile function after bilateral nerve-sparing radical prostatectomy. J. Um]. (2003) 4(Suppl.):375.
  • RAINA R, LAKIN MM, AGARWAL A et al.: Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology (2003) 62(1):110–115.
  • BROCK G, NEHRA A, LIPSHULTZ LI et al.: Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. Um]. (2003) 170:1278–1283.
  • MONTORSI F, NATHAN HP, MCCULLOUGH A et al.: Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo-controlled trial. J. Um]. (2004) 172(3):1036–1041.
  • DERRY F, HULTLING C, SEFTEL AD,SIPSKI ML: Efficacy and safety of sildenafil citrate (Viagra) in men with erectile dysfunction and spinal cord injury. Urology (2002) 60(2 Suppl. 2)49–57.
  • GIULIANO F, HULTLING C, EL MASRY WS et al: Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Ann. Neurol (1999) 46(1):15–21.

Websites

  • http://www.fda.gov/cder/foi/nda/ 192003/21-40 0/Levitra.htm FDA review document.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.